Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CTMX
CYTOMX THERAPEUTICS, INC.
NASDAQ
$3.71
▲ UP 0.82% (0.03)

KEY STATISTICS

Market Cap$807.68 M
52w High$8.21
52w Low$1.90
Dividend Yield—
Frequency—
P/E-9.02
Volume2.30M
Shares Out.217.70M

COMPANY

LEADERSHIP

Sean A. McCarthy
CHIEF EXECUTIVE
Sean A. McCarthy

COMPENSATION 2026

Salary$675,290
Stock Awards$1,150,463
Incentive Plan Pay$749,572
All Other Comp.$5,000
Total$4,738,495

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 8, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
69

PRICE TARGET

Target High$16.00
Target Low$6.00
Target Median$11.50
Target Consensus$11.25

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$10.43M
NOV
5
THU

PRICE

$3.71 ▲ UP 0.82% (+$0.03)
$3.52$3.60$3.689:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM3.71

About CytomX Therapeutics, Inc.

https://www.cytomx.com ↗

CytomX Therapeutics is a US biopharma company developing antibody therapeutics using Probody technology for cancer, with multiple candidates in clinical trials and collaborations with major pharma companies.

INDUSTRY

Biotechnology

A PRODUCT CYTOMX THERAPEUTICS, INC. IS KNOWN FOR

Varsetatug masetecan (CX-2051)
Varsetatug masetecan (CX-2051)

Varseta-M is CytomX's investigational antibody-drug conjugate targeting EpCAM on solid tumors, currently in Phase 1 trials for late-line colorectal cancer.

COMPETITORS

COMPETITOR
ABBV COMPARE
ADCT COMPARE
GILD COMPARE
STRO COMPARE

Revenue by Products

IconPRODUCTQ1-2018Q2-2018Q3-2018Q1-2025
E G F R Products$43.7M $42.3M ▼— $8.4M ▼
Amgen Other Products$4.4M $4.2M ▼— —
License And Service— — $2.8M —

ETFS HOLDING THIS STOCK

ETFS HOLDING
121
LISTED HERE
19
RANKED BY POSITION SIZE
XBI
0.27% · 8.5M
VTS.AX
0.00% · 6.2M
XSU.TO
0.02% · 4.5M
LABU
0.18% · 283.3K
FFSM
0.06% · 281.8K
CANC
0.41% · 242.8K
XRSU.L
0.02% · 161.2K
DFMC
0.01% · 135.6K
BFOR
0.17% · 109.6K
BBC
0.76% · 104.2K
RSSL
0.02% · 85.3K
PRFZ
0.01% · 82.9K
EES
0.03% · 67.2K
AVSC
0.01% · 63.2K
TILT
0.00% · 16.9K
BIB
0.03% · 7.8K
VIRS
0.06% · 3.7K
USUE.DE
0.00% · 806
RESM
0.02% · 339

INSTITUTIONAL OWNERSHIP

SHARES OWNED
63.36%
HOLDERS
226
TOP 12 OF 226 · RANKED BY POSITION SIZE
Fmr LLC
32.0M sh · $150.19M
Vr Adviser, LLC
15.6M sh · $66.29M
Kynam Capital Management, LP
15.0M sh · $70.56M
Tang Capital Management LLC
11.1M sh · $35.3M
Bank Of America Corp /De/
10.2M sh · $47.95M
Perceptive Advisors LLC
10.1M sh · $47.46M
Vanguard Group Inc
8.9M sh · $28.54M
Orbimed Advisors LLC
8.5M sh · $26.99M
Point72 Asset Management, L.P.
7.9M sh · $37.01M
Commodore Capital LP
7.7M sh · $32.77M
State Street Corp
5.7M sh · $26.62M
Citadel Advisors LLC
5.4M sh · $25.41M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF LEGAL OFFICER
Carvajal Alejandra
Purchase · 450.0K shares
2026-08-03
★
OFFICER: CHIEF LEGAL OFFICER
Carvajal Alejandra
Purchase · 100.0K shares
2026-08-03
★
Carvajal Alejandra
— · —
2026-08-03
★
Fuchs Charles S.
— · —
2026-07-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 4
BUY 3
OUTPERFORM 1
8 GRADES IN THE LAST 12 MONTHS
JP Morgan OVERWEIGHT Guggenheim BUY HC Wainwright & Co. BUY Piper Sandler OVERWEIGHT Barclays OVERWEIGHT Jefferies BUY Wedbush OUTPERFORM Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
ERAS$16.14COMPARE
IOVA$8.68COMPARE
MBX$61.43COMPARE
AVBP$31.11COMPARE
MGTX$13.85COMPARE
REPL$15.02COMPARE
MLTX$14.92COMPARE
DNA$6.90COMPARE